製品名:Ethyl 8-bromo-5-chloroimidazo[1,2-c]pyrimidine-2-carboxylate

IUPAC Name:ethyl 8-bromo-5-chloroimidazo[1,2-c]pyrimidine-2-carboxylate

CAS番号:2369771-66-2
分子式:C9H7BrClN3O2
純度:95%+
カタログ番号:CM559578
分子量:304.53

包装単位 有効在庫 価格(USD) 数量
CM559578-1g in stock ŤŮIJŤ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:2369771-66-2
分子式:C9H7BrClN3O2
融点:-
SMILESコード:BrC1=CN=C(Cl)N2C=C(C(OCC)=O)N=C12
密度:
カタログ番号:CM559578
分子量:304.53
沸点:
MDL番号:
保管方法:

Category Infos

Imidazoles
Imidazole is an important five-membered nitrogen-containing heterocyclic compound. Among the numerous heterocyclic compounds, imidazole and its derivatives are regarded as a unique and multifaceted scaffold material due to their diverse applications in industrial, organic and pharmaceutical chemistry. Imidazoles interact in different ways with many therapeutic targets, enzymes and receptors in biological systems and thus exhibit a wide range of biological activities. In particular, several imidazoles can be used as clinical drugs to treat various types of cancer with high therapeutic efficacy. Furthermore, imidazoles are one of the most critical segments in the field of anti-covid-19 virus drug discovery due to their ability to interact with active targets in living systems.
Imidazole Manufacturer
As a professional imidazole manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.
Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

ORIC-944
ORIC-944 is a potent and selective allosteric inhibitor of PRC2 developed by ORIC Pharmaceuticals. Initiated dosing of ORIC-944 in combination with NUBEQA® (darolutamide) and in combination with ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer in first half of 2024. Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 in combinations with AR inhibitors for the treatment of prostate cancer.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products